Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes

doi:10.5246/jcps.2021.09.061

Abstract

Abstract:

A combinational therapeutic system that simultaneously administrates various pathways is preferred for anti-cancer treatment. In the present study, we successfully constructed a co-delivery system, multivesicular liposomes (MVLs) co-encapsulating doxorubicin (DOX) and luminespib (AUY922). A simple and accurate dual-wavelength spectrophotometric method was established for the determination of DOX and AUY922 in liposomal formulation. MVL-loading drugs were prepared by a multi-emulsion solvent evaporation method, which exhibited excellent physicochemical properties, such as particle size of 3–8 μm and high entrapment efficiency above 95% for DOX and 73% for AUY922. The synergetic cytotoxic effect for these two drugs was evaluated in MDA-MB-231 cells. The in vitro antitumor studies demonstrated the superior anti-proliferation activity of DOX and AUY922 with a combination index of 0.43, indicating a great synergistic effect. The experimental data suggested that combinational use of DOX and AUY922 within liposomes could be an effective way to develop efficient treatments of cancers.

Key words: Doxorubicin, Luminespib, Multivesicular liposomes, Combination therapy, Synergistic effect

Supporting:

Yajie Liu, Yu Wang, Jiajia Li, Xiaoqing Xu, Xinru Li. Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 736-742.

Figures/Tables 7

Table 1. The parameters of regression equations.

Table 2. Average particle size and D90 of MVLs.

Table 3. The IC50 values of free DOX, free AUY922, and MVLs encapsulating DOX and/or AUY922 against MDA-MB-231 cells.

References 9

[1]	Jessica A, K.; Min Suk, S.; Chan Yeong, H.; Young Jik, K. "Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv. Drug Deliv. Rev. 2016, 98, 3–18.
[2]	Hu, C.M.; Zhang, L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83, 1104–1111.
[3]	Bendell, J.C.; Jones, S.F.; Hart, L.; Pant, S.; Moyhuddin, A.; Lane, C.M.; Earwood, C.; Murphy, P.; Patton, J.; Penley, W.C.; Thompson, D.; Infante, J.R. A phase I study of the Hsp90 inhibitor AUY922 plus capecitabine for the treatment of patients with advanced solid tumors. Cancer Investig. 2015, 33, 477–482.
[4]	Kong, A.; Rea, D.; Ahmed, S.; Beck, J.T.; López López, R.; Biganzoli, L.; Armstrong, A.C.; Aglietta, M.; Alba, E.; Campone, M.; Hsu Schmitz, S.F.; Lefebvre, C.; Akimov, M.; Lee, S.C. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. Oncotarget. 2016, 7, 37680–37692.
[5]	Agyeman, A.S.; Jun, W.J.; Proia, D.A.; Kim, C.R.; Skor, M.N.; Kocherginsky, M.; Conzen, S.D. Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer. Horm. Cancer. 2016, 7, 114–126.
[6]	Park, K.S.; Oh, B.; Lee, M.H.; Nam, K.Y.; Jin, H.R.; Yang, H.; Choi, J.; Kim, S.W.; Lee, D.H. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. Cancer Lett. 2016, 372, 75–81.
[7]	Yang, H.; Lee, M.H.; Park, I.; Jeon, H.; Choi, J.; Seo, S.; Kim, S.W.; Koh, G.Y.; Park, K.S.; Lee, D.H. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Cancer Lett. 2017, 411, 19–26.
[8]	Hashida, S.; Yamamoto, H.; Shien, K.; Ohtsuka, T.; Suzawa, K.; Maki, Y.; Furukawa, M.; Soh, J.; Asano, H.; Tsukuda, K.; Miyoshi, S.; Kanazawa, S.; Toyooka, S. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncol. Rep. 2015, 33, 1499–504.
[9]	Mu, H.J.; Wang, Y.Y.; Chu, Y.C.; Jiang, Y.; Hua, H.C.; Chu, L.X.; Wang, K.L.; Wang, A.P.; Liu, W.H.; Li, Y.X.; Fu, F.H.; Sun, K.X. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv. 2018, 25, 1372–1383.

[1]	Kaisen Li, Rudong Wang, Yiwei Peng, Dawen Dong, Xianrong Qi. Riboflavin-modified lipo-polyplexes co-delivering CXCR4 siRNA and doxorubicin for treatment of highly metastatic cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 189-205.
[2]	Chuhang Zhou, Xinping Hu, Qi Liu, Leqi Wang, Yuanhang Zhou, Yao Jin, Yan Liu. Enhanced tumor-targeted delivery of anticancer drugs by folic acid-conjugated pH-sensitive polymeric micelles [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 626-636.
[3]	Junsheng Xue, Siyuan Wang, Fangran Hao, Xiuyun Tian, Hong Su, Liang Yang, Qiming An, Chunyi Hao, Tianyan Zhou. Dopamine increases the anti-cancer efficacy of sunitinib in the treatment of pancreatic cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 689-700.
[4]	Xueling Wang, Yanqin Liang, Yuan Zhang, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang. Combination therapy of cRGD-DOX self-assembled nanoparticles and bevacizumab for breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(9): 627-640.
[5]	Haitao Hou, Zibing Song, Jieqin Ding, Dengguo Wei, Sheng Hu, Qianqian Zhai, Xiali Yue. Berberine enhances the activity of Sunitinib by targeting telomere G-quadruplex [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 289-297.
[6]	Zhantao Li, Ai Liao, Man Liu, Shuang Zhang, Zhenhan Feng, Guangxue Wang, Jingru Wang, Meiqi Xu, Zhuoyue Li, Xiaochuan Duan, Yanli Hao, Xiuchai Zheng, Hui Li, Qin Na, Hua Zhang, Bilin Liu, Xuan Zhang. Synthesis of poly(amidoamine)-poly(ethyleneglycol)-poly(amidoamine) and preparation of its hydrogel solution containing doxorubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 316-328.
[7]	Yang Zou, Yao Jin, Yuanhang Zhou, Chuyu He, Yunqiang Deng, Shidi Han, Chuhang Zhou, Xinru Li, Yanxia Zhou, Yan Liu. Preparation and characterization of dual pH-sensitive polymer-doxorubicin conjugate micelles [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(8): 530-539.
[8]	Maoyuan Song, Yuanyuan Zhang, Wenxi Zhang, Guanghua Peng, Jiaxing Wang, Mengya Yin, Jiajia Li, Yajie Liu, Xinru Li. Preparation, characterization and evaluation of multi-component-loaded liposomes containing Tat-TOS, phospholipase D inhibitor and doxorubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(5): 332-341.
[9]	Jiongxi Lei, Shuangchen Cong, Maoyuan Song, Wenxi Zhang, Guanghua Peng, Yuanyuan Zhang, Mengya Yin, Jiaxing Wang, Jiajia Li, Xinru Li. Preparation, characterization and evaluation of liposomal doxorubicin and harmine that show synergistic activity in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 666-674.
[10]	Qiao Zou, Yifan Chen, Xiaoqing Zheng, Binyuan Xu, Yuxi Liu, Huihui Zeng. Butaselen and cisplatin synergistically inhibit human cancer cells proliferation [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(8): 595-604.
[11]	Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833.
[12]	Jialin Li, Liying Guo, Xiaoya Qin, Tianyuan Fan. A simple and sensitive gradient elution liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for the quantification of doxorubicin in rabbit plasma [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 576-581.
[13]	Yuanxin Li, Zifei Han, Chao Tian, Zhili Zhang, Junyi Liu. Design, synthesis and evaluation of novel non-ATP competitive CHK1 inhibitors as chemotherapy sensitizing agents [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(10): 726-736.
[14]	Qingdan Xue, Aixia Ju, Yuhong Kang, Chunyu Zheng, Qiuhong Li. Effects of co-administraton of neferine and doxorubicin on the pharmacokinetics of doxorubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(4): 225-230.
[15]	Xiaoyou Wang, Xianhui Chen, Xiucong Yang, Bing He, Wenbing Dai, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang. A mechanism study on the tamoxifen-mediated cellular internalization of liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(9): 595-600.